# Ronovo Surgical

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/ronovo-surgical

- Industry: Medical Devices & Equipment
- Headquarters: Shanghai, China
- Website: www.ronovosurgical.com/
- Total disclosed funding: $108M
- Latest round: Series D (Sep 5, 2025)
- Investors on record: 10

## About

Established in 2019, and based in Shanghai, China, Ronovo Surgical is a medical medical technology that focuses on the research and development of surgical robots. The team members have worked at Johnson & Johnson, Medtronic, and KUKA. In early 2025, Ronovo Surgical raised series C funding led by Granite Asia. In September 2025, Ronovo Surgical raised USD 67 million of Series D funding from Johnson & Johnson Innovation, including Lilly Asia Ventures, Granite Asia, and INCE Capital.

The company is committed to providing minimally invasive surgical robots and digital surgery solutions for hospitals. The products include laparoscopic surgical robot systems, endoscopic imaging systems, surgical instruments, etc. The modular surgical robots have passed type inspection and GLP (Good Laboratory Practice) animal experiments. 

The company generates revenue by providing minimally invasive surgical robots and digital surgery solutions.

The organization plans to use the September 2025 funding to further advance innovation in surgical medical technology and expand its market presence.

## Funding rounds

- Series D, Sep 5, 2025, $67M — Granite Asia, Johnson & Johnson Innovation, Lilly Asia Ventures, INCE Capital
- Series C, Feb 1, 2025 — Granite Asia
- Series B, Jun 14, 2024, $41M — INCE Capital, Guolian Tongbao Capital, LongRiver Investments, King Star Med
- Series A, Apr 23, 2021 — Vivo Capital, Lilly Asia Ventures, MPC, Jiyuan Capital
- Seed, Nov 21, 2019 — Lilly Asia Ventures

## Investors

- Lilly Asia Ventures (https://capitalatlas.ai/funds/lilly-asia-ventures) — Seed, Series A, Series D
- Vivo Capital (https://capitalatlas.ai/funds/vivo-capital) — Series A
- MPC — Series A
- Jiyuan Capital (https://capitalatlas.ai/funds/jiyuan-capital) — Series A
- INCE Capital (https://capitalatlas.ai/funds/ince-capital) — Series B, Series D
- Guolian Tongbao Capital (https://capitalatlas.ai/funds/guolian-tongbao-capital) — Series B
- LongRiver Investments (https://capitalatlas.ai/funds/longriver-investments) — Series B
- King Star Med (https://capitalatlas.ai/funds/king-star-med) — Series B
- Granite Asia (https://capitalatlas.ai/funds/granite-asia) — Series C, Series D
- Johnson & Johnson Innovation (https://capitalatlas.ai/funds/johnson-johnson-innovation) — Series D